Cardiol Therapeutics Announces Plans for Orphan Drug Program in Acute Myocarditis with CardiolRx CBD Formulation
pharmaceutical investing Cardiol Therapeutics: A Leader in Research and Commercial Development of Pharmaceutical Cannabidiol Products and Targeted Therapies for Heart Failure and Cancer
Cardiol Therapeutics Completes Initial Public Offering and the Company’s Common Shares and Warrants Commence Trading on the Toronto Stock Exchange Under the Symbols “CRDL” and “CRDL.WT”
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
